Literature DB >> 22329595

Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening.

H Hu1, C Harmer, S Anuj, C E Wainwright, J Manos, J Cheney, C Harbour, I Zablotska, L Turnbull, C B Whitchurch, K Grimwood, B Rose.   

Abstract

Studies of the type 3 secretion system (T3SS) in Pseudomonas aeruginosa isolates from chronically infected older children and adults with cystic fibrosis (CF) show a predominantly exoS+/exoU- (exoS+) genotype and loss of T3SS effector secretion over time. Relatively little is known about the role of the T3SS in the pathogenesis of early P. aeruginosa infection in the CF airway. In this longitudinal study, 168 P. aeruginosa isolates from 58 children diagnosed with CF following newborn screening and 47 isolates from homes of families with or without children with CF were genotyped by pulsed-field gel electrophoresis (PFGE) and T3SS genotype and phenotype determined using multiplex PCR and western blotting. Associations were sought between T3SS data and clinical variables and comparisons made between T3SS data of clinical and environmental PFGE genotypes. Seventy-seven of the 92 clinical strains were exoS+ (71% secretors (ExoS+)) and 15 were exoU+ (93% secretors (ExoU+)). Initial exoS+ strains were five times more likely to secrete ExoS than subsequent exoS+ strains at first isolation. The proportion of ExoS+ strains declined with increasing age at acquisition. No associations were found between T3SS characteristics and gender, site of isolation, exacerbation, a persistent strain or pulmonary outcomes. Fourteen of the 23 environmental strains were exoS+ (79% ExoS+) and nine were exoU+ (33% ExoU+). The exoU+ environmental strains were significantly less likely to secrete ExoU than clinical strains. This study provides new insight into the T3SS characteristics of P. aeruginosa isolated from the CF airway early in life.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22329595     DOI: 10.1111/j.1469-0691.2012.03770.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  13 in total

1.  Type III secretion system and virulence markers highlight similarities and differences between human- and plant-associated pseudomonads related to Pseudomonas fluorescens and P. putida.

Authors:  Sylvie Mazurier; Annabelle Merieau; Dorian Bergeau; Victorien Decoin; Daniel Sperandio; Alexandre Crépin; Corinne Barbey; Katy Jeannot; Maïté Vicré-Gibouin; Patrick Plésiat; Philippe Lemanceau; Xavier Latour
Journal:  Appl Environ Microbiol       Date:  2015-01-30       Impact factor: 4.792

2.  Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs.

Authors:  Peter Jorth; Benjamin J Staudinger; Xia Wu; Katherine B Hisert; Hillary Hayden; Jayanthi Garudathri; Christopher L Harding; Matthew C Radey; Amir Rezayat; Gilbert Bautista; William R Berrington; Amanda F Goddard; Chunxiang Zheng; Angus Angermeyer; Mitchell J Brittnacher; Jacob Kitzman; Jay Shendure; Corinne L Fligner; John Mittler; Moira L Aitken; Colin Manoil; James E Bruce; Timothy L Yahr; Pradeep K Singh
Journal:  Cell Host Microbe       Date:  2015-08-20       Impact factor: 21.023

3.  Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.

Authors:  J Manos; H Hu; B R Rose; C E Wainwright; I B Zablotska; J Cheney; L Turnbull; C B Whitchurch; K Grimwood; C Harmer; S N Anuj; C Harbour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-07       Impact factor: 3.267

Review 4.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

5.  Cheating by type 3 secretion system-negative Pseudomonas aeruginosa during pulmonary infection.

Authors:  Kamila Czechowska; Saria McKeithen-Mead; Khatoun Al Moussawi; Barbara I Kazmierczak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

Review 6.  Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.

Authors:  Teiji Sawa; Masaru Shimizu; Kiyoshi Moriyama; Jeanine P Wiener-Kronish
Journal:  Crit Care       Date:  2014-12-13       Impact factor: 9.097

7.  Pseudomonas aeruginosa isolates from dental unit waterlines can be divided in two distinct groups, including one displaying phenotypes similar to isolates from cystic fibrosis patients.

Authors:  Myriam M Ouellet; Annie Leduc; Christine Nadeau; Jean Barbeau; Steve J Charette
Journal:  Front Microbiol       Date:  2015-01-21       Impact factor: 5.640

8.  The Pseudomonas aeruginosa type III translocon is required for biofilm formation at the epithelial barrier.

Authors:  Cindy S Tran; Stephanie M Rangel; Henrik Almblad; Arlinet Kierbel; Michael Givskov; Tim Tolker-Nielsen; Alan R Hauser; Joanne N Engel
Journal:  PLoS Pathog       Date:  2014-11-06       Impact factor: 6.823

9.  Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins.

Authors:  Gabriel Torrens; Isabel M Barceló; Marcelo Pérez-Gallego; Maria Escobar-Salom; Sara Tur-Gracia; Marta Munar-Bestard; María Del Mar González-Nicolau; Yoandy José Cabrera-Venegas; Estefany Nayarith Rigo-Rumbos; Gabriel Cabot; Carla López-Causapé; Estrella Rojo-Molinero; Antonio Oliver; Carlos Juan
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

10.  The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patients.

Authors:  Michel Ledizet; Thomas S Murray; Sailaja Puttagunta; Martin D Slade; Vincent J Quagliarello; Barbara I Kazmierczak
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.